Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Eliquis (apixaban) for Prevention of Stroke in Nonvalvular Atrial Fibrillation (NVAF) Patients

Drug (Brand / Generic)

Eliquis / apixaban

Company / Licensee

Bristol-Myers Squibb and Pfizer

Therapy Class

Anticoagulant

Current Indication

Nonvalvular Atrial Fibrillation (NVAF)

Market Sector

Cardiovascular

Development Status

Approved in Europe and US
Expand

Go Top